

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE, SUITE 2400 AUSTIN, TEXAS 78701-3271 WWW.FULBRIGHT.COM

MKRAWZSENEK@FULBRIGHT.COM DIRECT DIAL: (512) 536-3020 TELEPHONE:

(512) 474-5201

FACSIMILE:

(512) 536-4598

April 6, 2004

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

April 6, 2004

Date

Michael R. Krawzsenek

MS DD

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

RE:

U.S. Patent Application No. 10/670,907 entitled "METHODS OF PREPARING"

PHARMACEUTICAL DOSAGE FORMS CONTAINING MULTIPLE ACITVE INGREDIENTS" -

Giséle Veilleux et al.

Our reference: GOUD:037US Client reference: AML/11621.87

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and reference A1-A5, B2-B3 and C1.

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/GOUD:037US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Michael R. Krawzsenek

ichaell. Kangemen

Reg. No. 51,898

MRK/kmv

Encl.: as noted

dim

25400727.1



N THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Giséle Veilleux et al.

Serial No.: 10/670,907

Filed: September 25, 2003

For: METHOD OF PREPARING

PHARMACEUTICAL DOSAGE FORMS CONTAINING MULTIPLE ACTIVE

INGREDIENTS

Group Art Unit: 1615

Examiner: Unknown

Atty. Dkt. No.: GOUD:037US

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to:, MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

Michael R. Krawzsenek

April 6, 2004

Date

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS DD

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to

patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the

receipt of a first Official Action reflecting an examination on the merits, and hence is believed to

be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in

connection with the filing of this Supplemental Information Disclosure Statement, however,

should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to

these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright &

Jaworski Deposit Account No.: 50-1212/GOUD:037US.

Applicants respectfully request that the listed documents be made of record in the present

case.

Respectfully submitted,

Michael R. Krawzsenek

Reg. No. 51,898

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

April 6, 2004

| O I P Com | PTC |
|-----------------|-------|
| APR 0 9 20biste | Pate |
| | , |
| TRADEMARK OF Y | NFOR. |

n PTO-1449 (modified)

Patents and Publications for Applicant's

NFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No. GOUD:037US

Serial No. 10/670,907

Applicant

Giséle Veilleux et al.

September 25, 2003

Filing Date:

Group: 1615

U.S. Patent Documents
See Page 1

Foreign Patent Documents

See Page 1

Other Art See Page 1

U.S. Patent Documents

| Exam. Init. | Ref. Des. | Document Number | Date | Name | Class | Sub Class | Filing Date of App. |
|----------------|--------------|--------------------|----------|-------------------|-------|--------------|---------------------|
| | Al | 5,851,550 | 12/22/98 | Martin and Romero | 424 | 464 | 10/09/96 |
| | A2 | 5,861,172 | 1/19/99 | Martin and Romero | 424 | 464 | 10/08/96 |
| | A3 | 6,063,403 | 5/16/00 | de Haan and Thys | 424 | 464 | 6/18/96 |
| | A4 | 6,340,695 | 1/22/02 | Gervais | 514 | 345 | 6/21/01 |
| • | A5 | 6,352,720 | 3/05/02 | Martin and Romero | 424 | 464 | 8/24/00 |

Foreign Patent Documents

| Exam. Init. | Ref. Des. | Document Number | Date | Country | Class | Sub Class | Translation Yes/No |
|----------------|--------------|--------------------|---------|---------|-------|--------------|-----------------------|
| | B2 | EP 1 093 813 | 4/25/01 | Europe | | | English |
| | В3 | WO 02/053133 | 7/11/02 | PCT | | | English |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation | | | |
|----------------|--------------|---|--|--|--|
| | C1 | Bishai et al., "The efficacy and safety of Diclectin (Doxylamin/Pyridoxine) for nausea and vomiting of pregnancy," <i>Today's Therapeutic Trends</i> , Princeton Junction, NJ, 17(2):167-179, 1999. | | | |

25400713.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.